0001127602-23-029515.txt : 20231212
0001127602-23-029515.hdr.sgml : 20231212
20231212204620
ACCESSION NUMBER: 0001127602-23-029515
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231208
FILED AS OF DATE: 20231212
DATE AS OF CHANGE: 20231212
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LAURENCIN CATO T
CENTRAL INDEX KEY: 0001444810
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35299
FILM NUMBER: 231482790
MAIL ADDRESS:
STREET 1: C/O UNIVERSITY OF CONNECTICUT
STREET 2: 263 FARMINGTON AVENUE
CITY: FARMINGTON
STATE: CT
ZIP: 06030-3800
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Alkermes plc.
CENTRAL INDEX KEY: 0001520262
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 981007018
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: CONNAUGHT HOUSE
STREET 2: 1 BURLINGTON ROAD
CITY: DUBLIN 4
STATE: L2
ZIP: 00000
BUSINESS PHONE: 00-353-1-772-8000
MAIL ADDRESS:
STREET 1: CONNAUGHT HOUSE
STREET 2: 1 BURLINGTON ROAD
CITY: DUBLIN 4
STATE: L2
ZIP: 00000
FORMER COMPANY:
FORMER CONFORMED NAME: ANTLER SCIENCE TWO PLC
DATE OF NAME CHANGE: 20110804
FORMER COMPANY:
FORMER CONFORMED NAME: Antler Science Two Ltd
DATE OF NAME CHANGE: 20110509
4
1
form4.xml
PRIMARY DOCUMENT
X0508
4
2023-12-08
0001520262
Alkermes plc.
ALKS
0001444810
LAURENCIN CATO T
CONNAUGHT HOUSE
1 BURLINGTON ROAD
DUBLIN
4 Ireland
1
0
Ordinary Shares
2023-12-08
4
M
0
4163
A
16169
D
Ordinary Shares
2023-12-08
4
F
0
1000
25.86
D
15169
D
Non Qualified Stock Option (Right to Buy)
22.52
2023-11-17
5
J
0
E
112
22.52
A
2031-12-08
Ordinary Shares
112
5712
D
Non Qualified Stock Option (Right to Buy)
22.52
2023-11-17
5
J
0
E
422
22.52
A
2031-12-08
Ordinary Shares
422
21523
D
Non Qualified Stock Option (Right to Buy)
30.863
2023-11-17
5
J
0
E
231
30.863
A
2032-07-07
Ordinary Shares
231
11785
D
Non Qualified Stock Option (Right to Buy)
30.716
2023-11-17
5
J
0
E
254
30.716
A
2024-06-29
2033-06-29
Ordinary Shares
254
12986
D
Restricted Stock Unit Award
2023-11-17
5
J
0
E
119
A
2024-06-29
Ordinary Shares
119
6104
D
Restricted Stock Unit Award
2023-11-17
5
J
0
E
163
A
Ordinary Shares
163
8326
D
Restricted Stock Unit Award
2023-12-08
4
M
0
4163
D
Ordinary Shares
4163
4163
D
Each restricted stock unit represents a contingent right to receive one ordinary share.
Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.
This award is fully vested in accordance with its terms.
Shares subject to the stock option award vest in three equal annual installments commencing on 12/8/2022.
These options are fully vested in accordance with their terms.
Shares subject to the stock option award vest and become exercisable in full on 6/29/2024.
Shares subject to the restricted stock unit award vest in full on 6/29/2024.
Shares subject to the restricted stock unit award vest in three annual installments commencing on 12/8/2022.
/s/ Shantale Greenson, attorney-in-fact for Cato T. Laurencin
2023-12-12